Skip to content
Screener

Glaukos GKOS Restricted Cash

Restricted Cash at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$10.2M-48.5%
Bausch + Lomb logo
Bausch + LombBLCO
$11M+83.3%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.61M0.0%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$6.18M0.0%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$13M-43.5%
Boston Scientific logo
Boston ScientificBSX
$71M-31.1%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.08B+98.7%
Enterprise value$10.07B+98.2%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashAndCashEquivalentsNoncurrent.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemJune 30, 2026December 31, 2025
Inventory59,30663,564
Prepaid expenses and other current assets31,34624,052
Total current assets515,778474,984
Restricted cash3,1153,834
Property and equipment, net112,114113,253
Operating lease right-of-use asset31,27131,527
Finance lease right-of-use asset38,19739,404
Intangible assets, net127,151141,916

Item 1. Financial Statements

FAQ

What is Glaukos's restricted cash?
Glaukos (GKOS) reported restricted cash of $3.12M in Q2 2026.
How has Glaukos's restricted cash changed year-over-year?
Glaukos's restricted cash decreased by 18.8% year-over-year, from $3.83M to $3.12M.
What is the long-term trend for Glaukos's restricted cash?
Over 5 years (2020 to 2025), Glaukos's restricted cash has grown at a -16.7% compound annual growth rate (CAGR), from $9.57M to $3.83M.
What does restricted cash mean?
Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.

Ask your AI about Glaukos's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude